Physiological trials with MIF-I in Parkinson's disease (author's transl)
The writers present some physiological (and not therapeutic) acute and sub-acute trials with tripeptide: L-propyl-L-leucyl-glycine amide (M.I.F.-I) in Parkinson's Disease. This work confirms the earlier observation that M.I.F.-I employed alone or in combination with Levodopa is active against Parkinson's disease. The writers evoke the hypothesis that this action takes place at the postsynaptic receptors, whose configuration may be modified in the sense of a hypersensitivity. These studies justify undertaking a series of controlled therapeutic trials when the cost of the product permits and as well instituting development work on analogues active orally.
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
1978 |
---|---|
Erschienen: |
1978 |
Enthalten in: |
Zur Gesamtaufnahme - volume:134 |
---|---|
Enthalten in: |
Revue neurologique - 134(1978), 2 vom: 15. Feb., Seite 141-9 |
Sprache: |
Französisch |
---|
Weiterer Titel: |
Essais physiologiques avec le M.I.F.-I dans la maladie de Parkinson |
---|
Beteiligte Personen: |
Gonce, M [VerfasserIn] |
---|
Themen: |
9002-79-3 |
---|
Anmerkungen: |
Date Completed 18.11.1978 Date Revised 15.11.2007 published: Print Citation Status MEDLINE |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
NLM000303682 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM000303682 | ||
003 | DE-627 | ||
005 | 20231221010439.0 | ||
007 | tu | ||
008 | 231221s1978 xx ||||| 00| ||fre c | ||
028 | 5 | 2 | |a pubmed24n0001.xml |
035 | |a (DE-627)NLM000303682 | ||
035 | |a (NLM)29330 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a fre | ||
100 | 1 | |a Gonce, M |e verfasserin |4 aut | |
245 | 1 | 0 | |a Physiological trials with MIF-I in Parkinson's disease (author's transl) |
246 | 3 | 3 | |a Essais physiologiques avec le M.I.F.-I dans la maladie de Parkinson |
264 | 1 | |c 1978 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a Date Completed 18.11.1978 | ||
500 | |a Date Revised 15.11.2007 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a The writers present some physiological (and not therapeutic) acute and sub-acute trials with tripeptide: L-propyl-L-leucyl-glycine amide (M.I.F.-I) in Parkinson's Disease. This work confirms the earlier observation that M.I.F.-I employed alone or in combination with Levodopa is active against Parkinson's disease. The writers evoke the hypothesis that this action takes place at the postsynaptic receptors, whose configuration may be modified in the sense of a hypersensitivity. These studies justify undertaking a series of controlled therapeutic trials when the cost of the product permits and as well instituting development work on analogues active orally | ||
650 | 4 | |a Clinical Trial | |
650 | 4 | |a English Abstract | |
650 | 4 | |a Journal Article | |
650 | 7 | |a Antiparkinson Agents |2 NLM | |
650 | 7 | |a Melanocyte-Stimulating Hormones |2 NLM | |
650 | 7 | |a 9002-79-3 |2 NLM | |
650 | 7 | |a MSH Release-Inhibiting Hormone |2 NLM | |
650 | 7 | |a 9083-38-9 |2 NLM | |
700 | 1 | |a Barbeau, A |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Revue neurologique |d 1946 |g 134(1978), 2 vom: 15. Feb., Seite 141-9 |w (DE-627)NLM000303674 |x 0035-3787 |7 nnns |
773 | 1 | 8 | |g volume:134 |g year:1978 |g number:2 |g day:15 |g month:02 |g pages:141-9 |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 134 |j 1978 |e 2 |b 15 |c 02 |h 141-9 |